NCT05035745View on ClinicalTrials.gov

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
Interventions
DRUG

Talazoparib

Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)

DRUG

Selinexor

Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER